Indeed, recent clinical findings for patients with NSCLC treated with anti-PD-1 immunotherapy found that a higher Ki-67 expression level among PD-1+ CD8+ T-cells was a predictor for superior durable clinical benefit and survival rate35,36. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.